;PMID: 6090441
;source_file_836.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..40]
;1)sentence:[e:47..172] = [t:47..172]
;2)section:[e:176..196] = [t:176..195]
;3)sentence:[e:200..414] = [t:200..414]
;4)sentence:[e:415..512] = [t:415..512]
;5)sentence:[e:514..611] = [t:514..611]
;6)sentence:[e:612..811] = [t:612..811]
;7)sentence:[e:812..1069] = [t:812..1069]
;8)sentence:[e:1070..1258] = [t:1070..1258]
;9)sentence:[e:1259..1379] = [t:1259..1379]
;10)sentence:[e:1380..1528] = [t:1380..1528]
;11)sentence:[e:1529..1622] = [t:1529..1622]
;12)sentence:[e:1623..1983] = [t:1623..1983]
;13)section:[e:1987..2031] = [t:1987..2030]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:0..41][t:0..40]
;ERROR_Section end mismatch[e:176..196][t:176..195]
;ERROR_Section end mismatch[e:1987..2031][t:1987..2030]
;Token/POS Errors
;ERROR_Token in entity file but not tree[40..41] .
;ERROR_Token in entity file but not tree[195..196] .
;ERROR_Token in entity file but not tree[2030..2031] ]

;section 0 Span:0..40
;J Biol Chem. 1984 Oct 10;259(19):11654-7
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[13..17] 1984) (NNP:[18..21] Oct) (CD:[22..24] 10) (::[24..25] ;)
        (CD:[25..28] 259) (-LRB-:[28..29] -LRB-) (CD:[29..31] 19)
        (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..38] 11654) (::[38..39] -)
        (CD:[39..40] 7)))

(ORPH .)

;sentence 1 Span:47..172
;Luteinizing hormone and cyclic AMP-mediated induction of microsomal
;cytochrome  P-450 enzymes in cultured mouse Leydig cells.
;[47..66]:substance:"Luteinizing hormone"
;[71..81]:substance:"cyclic AMP"
;[115..140]:cyp450:"cytochrome  P-450 enzymes"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP
           (VBG:[47..58] Luteinizing) (NN:[59..66] hormone)
          (ADJP-1 (-NONE-:[66..66] *P*)))
        (NML-2 (-NONE-:[66..66] *P*)))
      (CC:[67..70] and)
      (NP
        (ADJP
           (JJ:[71..77] cyclic) (NN:[78..81] AMP)
          (ADJP-1 (HYPH:[81..82] -) (VBN:[82..90] mediated)))
        (NML-2 (NN:[91..100] induction))))
    (PP (IN:[101..103] of)
      (NP (JJ:[104..114] microsomal)
        
        (NML (NN:[115..125] cytochrome) (NN:[127..132] P-450))
        (NNS:[133..140] enzymes)))
    (PP-LOC (IN:[141..143] in)
      (NP (VBN:[144..152] cultured) (NN:[153..158] mouse) (NN:[159..165] Leydig)
          (NNS:[166..171] cells)))
    (.:[171..172] .)))
;ERROR_Orphan Text from Tree File[40..47] .

;section 2 Span:176..195
;Malaska T, Payne AH
(SEC
  (FRAG (NNP:[176..183] Malaska) (NNP:[184..185] T) (,:[185..186] ,)
        (NNP:[187..192] Payne) (NNP:[193..195] AH)))

(ORPH .)

;sentence 3 Span:200..414
;Treatment of mouse Leydig cell cultures with luteinizing hormone (LH) or with
; 8-bromo-cAMP (8-Br-cAMP) for 5 days elicited a dose- and time-dependent
;increase  in the microsomal cytochrome P-450 enzyme activities.
;[245..264]:substance:"luteinizing hormone"
;[266..268]:substance:"LH"
;[279..291]:substance:"8-bromo-cAMP"
;[293..302]:substance:"8-Br-cAMP"
;[308..309]:quantitative-value:"5"
;[310..314]:quantitative-units:"days"
;[379..402]:cyp450:"cytochrome P-450 enzyme"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[200..209] Treatment))
      (PP (IN:[210..212] of)
        (NP (NN:[213..218] mouse) (NN:[219..225] Leydig) (NN:[226..230] cell)
            (NNS:[231..239] cultures)))
      (PP
        (PP (IN:[240..244] with)
          (NP
            (NP (VBG:[245..256] luteinizing) (NN:[257..264] hormone))
            (NP (-LRB-:[265..266] -LRB-) (NN:[266..268] LH)
                (-RRB-:[268..269] -RRB-))))
        (CC:[270..272] or)
        (PP (IN:[273..277] with)
          (NP
            (NP (NN:[279..291] 8-bromo-cAMP))
            (NP (-LRB-:[292..293] -LRB-) (NN:[293..302] 8-Br-cAMP)
                (-RRB-:[302..303] -RRB-)))))
      (PP-TMP (IN:[304..307] for)
        (NP (CD:[308..309] 5) (NNS:[310..314] days))))
    (VP (VBD:[315..323] elicited)
      (NP
        (NP (DT:[324..325] a)
          (NML
            (NML
              (NML (NN:[326..330] dose) (HYPH:[330..331] -)
                (ADJP-1 (-NONE-:[331..331] *P*)))
              (NML-2 (-NONE-:[331..331] *P*)))
            (CC:[332..335] and)
            (NML
              (NML (NN:[336..340] time) (HYPH:[340..341] -)
                (ADJP-1 (JJ:[341..350] dependent)))
              (NML-2 (NN:[351..359] increase)))))
        (PP (IN:[361..363] in)
          (NP (DT:[364..367] the) (JJ:[368..378] microsomal)
            
            (NML (NN:[379..389] cytochrome) (NN:[390..395] P-450))
            (NN:[396..402] enzyme)
            (NNS:[403..413] activities)))))
    (.:[413..414] .)))
;ERROR_Orphan Text from Tree File[195..200] .

;sentence 4 Span:415..512
;17 alpha-Hydroxylase and  C17-20 lyase as well as a parallel increase in
;testosterone production.
;[415..435]:cyp450:"17 alpha-Hydroxylase"
;[441..453]:cyp450:"C17-20 lyase"
;[488..500]:substance:"testosterone"
(SENT
  (NP
    (NP
      (NP (CD:[415..417] 17) (NN:[418..435] alpha-Hydroxylase))
      (CC:[436..439] and)
      (NP (NN:[441..447] C17-20) (NN:[448..453] lyase)))
    (CONJP (RB:[454..456] as) (RB:[457..461] well) (IN:[462..464] as))
    (NP
      (NP (DT:[465..466] a) (JJ:[467..475] parallel) (NN:[476..484] increase))
      (PP (IN:[485..487] in)
        (NP (NN:[488..500] testosterone) (NN:[501..511] production))))
    (.:[511..512] .)))

;sentence 5 Span:514..611
;Reduction of the oxygen tension from 19 to 1% resulted in a greater increase
;in  enzyme activity.
;[531..537]:substance:"oxygen"
;[551..559]:quantitative-value:"19 to 1%"
;[595..601]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[514..523] Reduction))
      (PP (IN:[524..526] of)
        (NP (DT:[527..530] the) (NN:[531..537] oxygen) (NN:[538..545] tension)))
      (PP (IN:[546..550] from)
        (NP (CD:[551..553] 19)
          (NML-1 (-NONE-:[553..553] *RNR*))))
      (PP (TO:[554..556] to)
        (NP (CD:[557..558] 1)
          (NML-1 (-NONE-:[558..558] *RNR*))))
      (NML-1 (NN:[558..559] %)))
    (VP (VBD:[560..568] resulted)
      (PP-CLR (IN:[569..571] in)
        (NP
          (NP (DT:[572..573] a) (JJR:[574..581] greater)
              (NN:[582..590] increase))
          (PP (IN:[591..593] in)
            (NP (NN:[595..601] enzyme) (NN:[602..610] activity))))))
    (.:[610..611] .)))

;sentence 6 Span:612..811
;Induction of microsomal cytochrome P-450 activities was 35 to  50% greater
;with 8-Br-cAMP than with LH and the increase in C17-20 lyase  activity was
;4-fold greater than that of 17 alpha-hydroxylase.
;[636..652]:cyp450:"cytochrome P-450"
;[668..678]:quantitative-value:"35 to  50%"
;[692..701]:substance:"8-Br-cAMP"
;[712..714]:substance:"LH"
;[735..747]:cyp450:"C17-20 lyase"
;[762..768]:quantitative-value:"4-fold"
;[790..810]:cyp450:"17 alpha-hydroxylase"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[612..621] Induction))
        (PP (IN:[622..624] of)
          (NP (JJ:[625..635] microsomal)
            (NML (NN:[636..646] cytochrome) (NN:[647..652] P-450))
            (NNS:[653..663] activities))))
      (VP (VBD:[664..667] was)
        (ADJP-PRD
          (ADJP
            (NP-ADV
              (QP (CD:[668..670] 35) (TO:[671..673] to) (CD:[675..677] 50))
              (NN:[677..678] %))
            (JJR:[679..686] greater))
          (PP (IN:[687..691] with)
            (NP (NN:[692..701] 8-Br-cAMP)))
          (PP (IN:[702..706] than)
            (PP (IN:[707..711] with)
              (NP (NN:[712..714] LH)))))))
    (CC:[715..718] and)
    (S
      (NP-SBJ
        (NP (DT:[719..722] the) (NN:[723..731] increase))
        (PP (IN:[732..734] in)
          (NP
            (NML (NN:[735..741] C17-20) (NN:[742..747] lyase))
            (NN:[749..757] activity))))
      (VP (VBD:[758..761] was)
        (ADJP-PRD
          (ADJP
            (ADVP (CD:[762..763] 4) (HYPH:[763..764] -) (RB:[764..768] fold))
            (JJR:[769..776] greater))
          (PP (IN:[777..781] than)
            (NP
              (NP (DT:[782..786] that))
              (PP (IN:[787..789] of)
                (NP (CD:[790..792] 17) (NN:[793..810] alpha-hydroxylase))))))))
    (.:[810..811] .)))

;sentence 7 Span:812..1069
;Maximal induction  of P-450 enzyme activities was observed between 3 and 5
;days of continual  treatment with 8-Br-cAMP or LH. Removal of 8-Br-cAMP from
;the culture medium  inhibited any further increase in C17-20 lyase activity
;and testosterone  production.
;[834..846]:cyp450:"P-450 enzyme"
;[871..886]:quantitative-value:"between 3 and 5"
;[887..891]:quantitative-units:"days"
;[921..930]:substance:"8-Br-cAMP"
;[934..936]:substance:"LH"
;[949..958]:substance:"8-Br-cAMP"
;[976..982]:substance:"medium"
;[1018..1030]:cyp450:"C17-20 lyase"
;[1044..1056]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[812..819] Maximal) (NN:[820..829] induction))
      (PP (IN:[831..833] of)
        (NP
          (NML (NN:[834..839] P-450) (NN:[840..846] enzyme))
          (NNS:[847..857] activities))))
    (VP (VBD:[858..861] was)
      (VP (VBN:[862..870] observed)
        (NP-2 (-NONE-:[870..870] *))
        (PP (IN:[871..878] between)
          (NP
            (NP
              (NP (CD:[879..880] 3)
                (NML-1 (-NONE-:[880..880] *P*)))
              (CC:[881..884] and)
              (NP (CD:[885..886] 5)
                (NML-1 (NNS:[887..891] days))))
            (PP (IN:[892..894] of)
              (NP
                (NP (JJ:[895..904] continual) (NN:[906..915] treatment))
                (PP (IN:[916..920] with)
                  (NP (NN:[921..930] 8-Br-cAMP) (CC:[931..933] or)
                      (NN:[934..936] LH)))))))))
    (.:[936..937] .))
  (S
    (NP-SBJ
      (NP (NN:[938..945] Removal))
      (PP (IN:[946..948] of)
        (NP (NN:[949..958] 8-Br-cAMP)))
      (PP (IN:[959..963] from)
        (NP (DT:[964..967] the) (NN:[968..975] culture) (NN:[976..982] medium))))
    (VP (VBD:[984..993] inhibited)
      (NP
        (NP (DT:[994..997] any) (JJ:[998..1005] further)
            (NN:[1006..1014] increase))
        (PP (IN:[1015..1017] in)
          (NP
            (NP
              (NML (NN:[1018..1024] C17-20) (NN:[1025..1030] lyase))
              (NN:[1031..1039] activity))
            (CC:[1040..1043] and)
            (NP (NN:[1044..1056] testosterone) (NN:[1058..1068] production))))))
    (.:[1068..1069] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[812..1069]::S:S:

;sentence 8 Span:1070..1258
;The role of protein synthesis in the induction process was  investigated by
;incubating Leydig cell cultures with and without cycloheximide  between 24
;and 48 h of treatment with 8-Br-cAMP.
;[1082..1089]:substance:"protein"
;[1195..1208]:substance:"cycloheximide"
;[1210..1227]:quantitative-value:"between 24 and 48"
;[1228..1229]:quantitative-units:"h"
;[1248..1257]:substance:"8-Br-cAMP"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1070..1073] The) (NN:[1074..1078] role))
      (PP (IN:[1079..1081] of)
        (NP (NN:[1082..1089] protein) (NN:[1090..1099] synthesis)))
      (PP (IN:[1100..1102] in)
        (NP (DT:[1103..1106] the) (NN:[1107..1116] induction)
            (NN:[1117..1124] process))))
    (VP (VBD:[1125..1128] was)
      (VP (VBN:[1130..1142] investigated)
        (NP-2 (-NONE-:[1142..1142] *))
        (PP-MNR (IN:[1143..1145] by)
          (S-NOM
            (NP-SBJ (-NONE-:[1145..1145] *))
            (VP (VBG:[1146..1156] incubating)
              (NP (NN:[1157..1163] Leydig) (NN:[1164..1168] cell)
                  (NNS:[1169..1177] cultures))
              (PP (IN:[1178..1182] with) (CC:[1183..1186] and)
                  (IN:[1187..1194] without)
                (NP (NN:[1195..1208] cycloheximide)))
              (PP-TMP (IN:[1210..1217] between)
                (NP
                  (NP
                    (NP (CD:[1218..1220] 24)
                      (NML-1 (-NONE-:[1220..1220] *P*)))
                    (CC:[1221..1224] and)
                    (NP (CD:[1225..1227] 48)
                      (NML-1 (NN:[1228..1229] h))))
                  (PP (IN:[1230..1232] of)
                    (NP
                      (NP (NN:[1233..1242] treatment))
                      (PP (IN:[1243..1247] with)
                        (NP (NN:[1248..1257] 8-Br-cAMP))))))))))))
    (.:[1257..1258] .)))

;sentence 9 Span:1259..1379
;Cycloheximide completely  inhibited the induction of C17-20 lyase activity
;and the increase in  testosterone production.
;[1259..1272]:substance:"Cycloheximide"
;[1312..1324]:cyp450:"C17-20 lyase"
;[1355..1367]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ (NN:[1259..1272] Cycloheximide))
    (VP
      (ADVP (RB:[1273..1283] completely))
      (VBD:[1285..1294] inhibited)
      (NP
        (NP
          (NP (DT:[1295..1298] the) (NN:[1299..1308] induction))
          (PP (IN:[1309..1311] of)
            (NP
              (NML (NN:[1312..1318] C17-20) (NN:[1319..1324] lyase))
              (NN:[1325..1333] activity))))
        (CC:[1334..1337] and)
        (NP
          (NP (DT:[1338..1341] the) (NN:[1342..1350] increase))
          (PP (IN:[1351..1353] in)
            (NP (NN:[1355..1367] testosterone) (NN:[1368..1378] production))))))
    (.:[1378..1379] .)))

;sentence 10 Span:1380..1528
;After removal of the inhibitor, cultures responded in a  manner that
;paralleled induction in cultures that had not been treated with 
;cycloheximide.
;[1401..1410]:substance:"inhibitor"
;[1514..1527]:substance:"cycloheximide"
(SENT
  (S
    (PP-TMP (IN:[1380..1385] After)
      (NP
        (NP (NN:[1386..1393] removal))
        (PP (IN:[1394..1396] of)
          (NP (DT:[1397..1400] the) (NN:[1401..1410] inhibitor)))))
    (,:[1410..1411] ,)
    (NP-SBJ (NNS:[1412..1420] cultures))
    (VP (VBD:[1421..1430] responded)
      (PP (IN:[1431..1433] in)
        (NP
          (NP (DT:[1434..1435] a) (NN:[1437..1443] manner))
          (SBAR
            (WHNP-2 (IN:[1444..1448] that))
            (S
              (NP-SBJ-2 (-NONE-:[1448..1448] *T*))
              (VP (VBD:[1449..1459] paralleled)
                (NP
                  (NP (NN:[1460..1469] induction))
                  (PP-LOC (IN:[1470..1472] in)
                    (NP
                      (NP (NNS:[1473..1481] cultures))
                      (SBAR
                        (WHNP-1 (WDT:[1482..1486] that))
                        (S
                          (NP-SBJ-1 (-NONE-:[1486..1486] *T*))
                          (VP (VBD:[1487..1490] had) (RB:[1491..1494] not)
                            (VP (VBN:[1495..1499] been)
                              (VP (VBN:[1500..1507] treated)
                                (NP-1 (-NONE-:[1507..1507] *))
                                (PP (IN:[1508..1512] with)
                                  (NP (NN:[1514..1527] cycloheximide)))))))))))))))))
    (.:[1527..1528] .)))

;sentence 11 Span:1529..1622
;In both cases, a 24-h lag period occurred prior to an increase in  cytochrome
;P-450 activity.
;[1546..1548]:quantitative-value:"24"
;[1549..1550]:quantitative-units:"h"
;[1596..1612]:cyp450:"cytochrome P-450"
(SENT
  (S
    (PP (IN:[1529..1531] In)
      (NP (DT:[1532..1536] both) (NNS:[1537..1542] cases)))
    (,:[1542..1543] ,)
    (NP-SBJ (DT:[1544..1545] a)
      (NML (CD:[1546..1548] 24) (HYPH:[1548..1549] -) (NN:[1549..1550] h))
      (NN:[1551..1554] lag) (NN:[1555..1561] period))
    (VP (VBD:[1562..1570] occurred)
      (PP-TMP (RB:[1571..1576] prior)
        (PP (TO:[1577..1579] to)
          (NP
            (NP (DT:[1580..1582] an) (NN:[1583..1591] increase))
            (PP (IN:[1592..1594] in)
              (NP
                (NML (NN:[1596..1606] cytochrome) (NN:[1607..1612] P-450))
                (NN:[1613..1621] activity)))))))
    (.:[1621..1622] .)))

;sentence 12 Span:1623..1983
;These data suggest that the increase in microsomal  cytochrome P-450
;activities represents an increase in enzyme synthesis and,  furthermore, that
;reduction of oxygen tension decreases degradation of newly  synthesized
;Leydig cell microsomal cytochrome P-450 activities as recently  reported
;(Quinn, P.G., and Payne, A.H. (1984) J. Biol. Chem. 259, 4130-4135).
;[1675..1691]:cyp450:"cytochrome P-450"
;[1729..1735]:cyp450:"enzyme"
;[1783..1789]:substance:"oxygen"
;[1865..1881]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ (DT:[1623..1628] These) (NNS:[1629..1633] data))
    (VP (VBP:[1634..1641] suggest)
      (SBAR
        (SBAR (IN:[1642..1646] that)
          (S
            (NP-SBJ
              (NP (DT:[1647..1650] the) (NN:[1651..1659] increase))
              (PP (IN:[1660..1662] in)
                (NP (JJ:[1663..1673] microsomal)
                  (NML (NN:[1675..1685] cytochrome) (NN:[1686..1691] P-450))
                  (NNS:[1692..1702] activities))))
            (VP (VBZ:[1703..1713] represents)
              (NP
                (NP (DT:[1714..1716] an) (NN:[1717..1725] increase))
                (PP (IN:[1726..1728] in)
                  (NP (NN:[1729..1735] enzyme) (NN:[1736..1745] synthesis)))))))
        (CC:[1746..1749] and) (,:[1749..1750] ,)
        (ADVP (RB:[1752..1763] furthermore))
        (,:[1763..1764] ,)
        (SBAR (DT:[1765..1769] that)
          (S
            (NP-SBJ
              (NP (NN:[1770..1779] reduction))
              (PP (IN:[1780..1782] of)
                (NP (NN:[1783..1789] oxygen) (NN:[1790..1797] tension))))
            (VP (VBZ:[1798..1807] decreases)
              (NP
                (NP (NN:[1808..1819] degradation))
                (PP (IN:[1820..1822] of)
                  (NP
                    (ADJP (RB:[1823..1828] newly) (VBN:[1830..1841] synthesized))
                    (NML (NN:[1842..1848] Leydig) (NN:[1849..1853] cell))
                    (JJ:[1854..1864] microsomal)
                    (NML (NN:[1865..1875] cytochrome) (NN:[1876..1881] P-450))
                    (NNS:[1882..1892] activities))))
              (SBAR (IN:[1893..1895] as)
                (S
                  (NP-SBJ-1 (-NONE-:[1895..1895] *))
                  (ADVP (RB:[1896..1904] recently))
                  (VP (VBD:[1906..1914] reported)
                    (NP-1 (-NONE-:[1914..1914] *))
                    (PRN (-LRB-:[1915..1916] -LRB-)
                      (FRAG (NNP:[1916..1921] Quinn) (,:[1921..1922] ,)
                            (NNP:[1923..1927] P.G.) (,:[1927..1928] ,)
                            (CC:[1929..1932] and) (NNP:[1933..1938] Payne)
                            (,:[1938..1939] ,) (NNP:[1940..1944] A.H.)
                            (-LRB-:[1945..1946] -LRB-) (CD:[1946..1950] 1984)
                            (-RRB-:[1950..1951] -RRB-) (NNP:[1952..1954] J.)
                            (NNP:[1955..1960] Biol.) (NNP:[1961..1966] Chem.)
                            (CD:[1967..1970] 259) (,:[1970..1971] ,)
                            (CD:[1972..1976] 4130) (HYPH:[1976..1977] -)
                            (CD:[1977..1981] 4135))
                      (-RRB-:[1981..1982] -RRB-))))))))))
    (.:[1982..1983] .)))

;section 13 Span:1987..2030
;PMID: 6090441 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[1987..1991] PMID) (::[1991..1992] :) (CD:[1993..2000] 6090441)
        (-LRB-:[2001..2002] -LSB-) (NNP:[2002..2008] PubMed) (::[2009..2010] -)
        (VBN:[2011..2018] indexed) (IN:[2019..2022] for)
        (NNP:[2023..2030] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[2030..EOF] ]

(ORPH -RSB-)
